Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]AZD4144 Solution for Infusion
AZD4144 for Infusion · 1 trial · 1 indication
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faeces and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity
Identification of greater than 80% of the radioactivity recovered in the urine and/or faeces
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | Participants in Cohort 1 will receive a single intravenous injection of \[14C\]AZD4144 Solution for Infusion |
| Regimen B | EXPERIMENTAL | Participants in Cohort 2 will receive a single oral dose of \[14C\]AZD4144 Oral Solution |
| Name | Type | Description |
|---|---|---|
| [14C]AZD4144 Solution for Infusion | DRUG | Intravenous, fasted |
| [14C]AZD4144 Oral Solution | DRUG | Oral, fasted |
Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * BMI of 18.0 to 32.0 kg/m2 inclusive * Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clin...
AZD4144 for Infusion is an investigational small molecule developed by AstraZeneca PLC. It is also known as [14C]AZD4144 Solution for Infusion, a radiolabeled form used in clinical research. The compound has been studied in a Phase 1 trial in healthy participants, and its therapeutic indication has not been disclosed.
AZD4144 for Infusion is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 clinical study of the compound. The drug remains an investigational agent in AstraZeneca's pipeline.
AZD4144 for Infusion is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 16 healthy participants. The drug is investigational and has not been approved for any indication.
AZD4144 for Infusion has been evaluated in one completed Phase 1 trial, NCT07518459, titled A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144. The trial enrolled 16 healthy participants in the United Kingdom, with participants aged 30 years and older, and used a controlled design.
Yes. AZD4144 for Infusion is also known as [14C]AZD4144 Solution for Infusion. The bracketed carbon-14 label indicates a radiolabeled version of the compound used to trace absorption, distribution, metabolism, and excretion in the Phase 1 ADME study. Both names refer to the same AstraZeneca investigational asset.